We take risks and challenge existing approaches, because for many patients, it’s the only chance

Welcome to ImmuVia


ImmuVia develops novel antibody-based targeted therapeutics to treat oncological diseases. Founded in 2017, ImmuVia works on developing cutting-edge therapeutic products that will make a difference in patients’ lives.

ImmuVia focuses on targeting tumors with high unmet medical need

Our aim is to improve efficacy, while avoiding toxicity


Building sturdy scientific foundations for exponential growth


Founded by Iosif M. Gershteyn & Victor S. Goldmacher.


First IP filings.


Private Seed Round Executed.


Seed Round Extension Secured.


Bridge Round & Corporate reorganization.


Founding Team

Victor S. Goldmacher, PhD

Chief Scientific Officer

Victor previously served as Senior Director and Head, Cell Biology, at ImmunoGen, and prior to that Assistant Professor of Pathology at Dana-Farber Cancer Institute & Harvard Medical School. At ImmunoGen, Victor built and managed a group of BS/MS and PhD scientists responsible for discovery and in vitro characterization and preclinical development of antibody-drug conjugates and antibodies. Three of his major achievements are discoveries of the FDA-approved antibody-drug conjugates Kadcyla® for the treatment of breast cancer, and ELAHERE™ for the treatment of platinum-resistant ovarian cancer, and of the FDA-approved antibody SARCLISA® for the treatment of multiple myeloma. Victor was one of the founding scientists of ImmunoGen. Victor is an inventor of 28 issued US Patents and more than 100 peer-reviewed publications in top scientific journals.

BSc/MSc, Chemistry – Moscow State University
PhD, Biochemistry – Moscow State University
Postdoctoral Research Fellow – Massachusetts Institute of Technology

Assistant Professor of Pathology – Harvard Medical School & Dana-Farber Cancer Institute
Head & Senior Director, Cell Biology Department – ImmunoGen
Director of Discovery – Forbius, Inc.


Iosif M. Gershteyn

Chief Executive Officer

Iosif M. Gershteyn is a serial entrepreneur with a track record of founding companies in the biologics (oncology) and medical device (pulmonology/telemedicine) industries. He successfully out-licensed internally generated IP in the medical device industry, executed a small business roll-up to scale an online retail company prior to co-founding ImmuVia. He started his career in asset management working on long-term qualitative investment strategies and subsequently worked in corporate strategy (including mergers and acquisitions). Alongside his primary occupation, he pursued interests in biology (neuroscience, immunology and physiology) after the completion of his formal education. These interests led him to found the Immunodietica project, and publishing research in the fields of immunology and computational systems biology.

BA/MA, Economics – Brandeis University / International Business School
Executive MBA – Quantic School of Business and Technology
Visiting Scholar – Medical University of South Carolina

Our Expert Team

ImmuVia’s world-class team is central in it’s continued success developing and advancing breakthrough therapeutics.

profile YK2

Yelena Kovtun, PhD

Head of Biology & Preclinical Development

Twenty-plus years of drug discovery or drug development experience in targeted cancer therapies, including developing the strategy for differentiation of next-generation antibody drug conjugates and directing Investigational New Drug (IND)-enabling studies. During her tenure at ImmunoGen, as Associate Director, Cell Biology and Preclinical Development, Yelena led the research portfolio of programs in hematological malignancies that advanced multiple compounds to the clinic. Yelena led the discovery and development of pivekimab sunirine (currently in Phase 2) from inception to IND submission. Yelena is an inventor of 10 issued US Patents and more than 25 peer-reviewed publications in top scientific journals.

BSc/MSc, Biochemistry – Taras Shevchenko National University of Kyiv
PhD, Molecular Biology – Ukrainian Academy of Sciences
Postdoctoral Research Fellow – Harvard Medical School

Без названия

Ravi Chari, PhD

Senior Advisor & Project Leader

Ravi has over 30 years of experience in all aspects of ADC and other delivery systems with a focus on Oncology. He is an inventor of 100 issued US Patents and more than 60 peer-reviewed publications in top scientific journals. Two of his major achievements are discoveries of the FDA-approved antibody-drug conjugates Kadcyla® for the treatment of breast cancer, and of ELAHERE™ for the treatment of platinum-Resistant ovarian cancer.

PhD, Chemistry, University of Detroit
Postdoctoral Research Fellow – Yale University School of Medicine
Research Scientist – Dana-Farber Cancer Institute


Godfrey Amphlett, PhD

Senior Advisor on Development & Regulatory Affairs

During his tenure at ImmunoGen in the capacity of Vice President, Godfrey was responsible for developing processes to manufacture and characterize components of ADCs and supporting regulatory filings from Phase 1 through commercialization. Prior to ImmunoGen, Godfrey, as Director at Genetics Institute, was responsible for the development of purification processes, analytical methods, and formulations for early and late phase biopharmaceuticals to commercialization, in particular, Erythropoietin; Coagulation Factor VIII; Coagulation Factor IX; Interleukin 11; and Bone Morphogenetic Protein 2.

BA, Natural Sciences – University of Cambridge
PhD, Biochemistry – University of Birmingham

RedSky Pauline 03 headshot cropped

Pauline Jen Ryan

Strategic Corporate Advisor

Pauline Jen Ryan is an Entrepreneur-in-Residence at Mass General Brigham Innovation and is on the Board of Directors and CEO of Atropos Therapeutics. Previously, she was Senior Vice President, Corporate Development & Operations at both Proteostasis Therapeutics and ImmunoGen, where she raised over $200M in equity funding and nearly $200M in corporate partnerships. She secured the partnerships with Genentech and Sanofi that created Kadcyla® for breast cancer and Sarclisa® for multiple myeloma. As a Partner at Red Sky Partners, she served in interim C-level roles (CEO, CBO, COO) including startups and companies leveraging “virtual” operating models. She has raised successful Series A rounds (notably Proteostasis Therapeutics – $45M, ZielBio – $25.1M).

BA, Psychology – Northwestern University
MBA – Kellogg Graduate School of Management


Leveraging decades of experience, our team has identified high-value targets and developed biologic agents for effective eradiation of malignant cells.


Targets are present in high density on cancer cells, and are not present on most normal cells.


Recombinant antibody-based proteins developed to induce self-destruction of targeted cells.


Innovative mode of tumor eradication.


Unlike ADCs, our molecules do not rely on internalization inside cells, nor on toxic payloads, and thus can kill drug-resistant cells.


Our molecules are fully compatible with standard antibody manufacturing processes, no chemical modification of the protein is involved.


No toxic chemicals, or proteins, nor recruitment of immune cells, which could cause dangerous side effects.